HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease

HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease

Recent clinical studies found a strong association of colonic inflammation and Inflammatory bowel disease (IBD)-like phenotype with NonAlcoholic Fatty liver Disease (NAFLD) yet the mechanisms remain unknown. The present study identifies high mobility group box 1 (HMGB1) as a key mediator of intestin...

Full description

Bibliographic Details
Main Authors:	Varun Chandrashekaran, Ratanesh K. Seth, Diptadip Dattaroy, Firas Alhasson, Jacek Ziolenka, James Carson, Franklin G. Berger, Balaraman Kalyanaraman, Anna Mae Diehl, Saurabh Chatterjee
Format:	Article
Language:	English
Published:	Elsevier 2017-10-01
Series:	Redox Biology
Subjects:	Nonalcoholic steatohepatitis DAMP FBA TLR4 Flotillin NADPH oxidase
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213231717302744

Similar Items

White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in MiceSummary
by: Sadatsugu Sakane, et al.
Published: (2021-01-01)

Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
by: Stephen D. H. Malnick, et al.
Published: (2022-12-01)

Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet
by: Jiwon Choi, et al.
Published: (2023-08-01)

Possible Development of Burn-Out Nonalcoholic Steatohepatitis under Long-Term Steroid Use
by: Soichiro Ota, et al.
Published: (2022-09-01)

Dietary and genetic disruption of hepatic methionine metabolism induce acid sphingomyelinase to promote steatohepatitis
by: Cristina Alarcón-Vila, et al.
Published: (2023-02-01)

Sulfate limitation increases specific plasmid DNA yield and productivity in E. coli fed-batch processes
by: Mathias Gotsmy, et al.
Published: (2023-11-01)

Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
by: Hwi Young Kim, et al.
Published: (2023-03-01)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01)

The role of the microbiome in NAFLD and NASH
by: Aleksandra A Kolodziejczyk, et al.
Published: (2019-02-01)

Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact
by: David Højland Ipsen, et al.
Published: (2021-01-01)

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth
by: Stéphanie Lacotte, et al.
Published: (2023-12-01)

Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
by: Hirokazu Takahashi, et al.
Published: (2023-04-01)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
by: Takemi Akahane, et al.
Published: (2021-11-01)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
by: Mindy C.W. Lam, et al.
Published: (2012-07-01)

Metabolically associated fatty liver disease – a disease of the 21st century: A review
by: Igor V. Maev, et al.
Published: (2022-07-01)

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2020-12-01)

MPP1 Determines the Mobility of Flotillins and Controls the Confinement of Raft-Associated Molecules
by: Agnieszka Biernatowska, et al.
Published: (2022-01-01)

Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
by: Reeju Amatya, et al.
Published: (2023-07-01)

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
by: Mohamed Salaheldin, et al.
Published: (2023-08-01)

Artificial Intelligence in NAFLD: Will Liver Biopsy Still Be Necessary in the Future?
by: Lei Zhang, et al.
Published: (2022-12-01)

ADEMETHIONINE IN THERAPY OF NON-ALCOHOLIC FATTY LIVER DISEASE
by: A. V. Polukhina, et al.
Published: (2017-11-01)

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
by: Margaret LP Teng, et al.
Published: (2023-04-01)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
by: Maria Sotiropoulou, et al.
Published: (2021-01-01)

Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?
by: Alessandro Mantovani, et al.
Published: (2016-02-01)

Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm
by: Chua, Damien, et al.
Published: (2023)

EFR3A: a new raft domain organizing protein?
by: Magdalena Trybus, et al.
Published: (2023-10-01)

In Silico Design Strategies for the Production of Target Chemical Compounds Using Iterative Single-Level Linear Programming Problems
by: Tomokazu Shirai, et al.
Published: (2022-04-01)

Involvement of Intracellular TAGE and the TAGE–RAGE–ROS Axis in the Onset and Progression of NAFLD/NASH
by: Akiko Sakasai-Sakai, et al.
Published: (2023-03-01)

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
by: Han Ah Lee, et al.
Published: (2023-05-01)

Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations
by: CM Oneta
Published: (2002-09-01)

Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
by: Wasitha P. D. W. Thilakarathna, et al.
Published: (2024-02-01)

Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet
by: Victoria Svop Jensen, et al.
Published: (2021-02-01)

Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
by: Moongi Ji, et al.
Published: (2022-07-01)

Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery
by: Marielle Malucelli, et al.
Published: (2023-11-01)

LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity
by: Laia Bertran, et al.
Published: (2023-06-01)

An Update on the Chemokine System in the Development of NAFLD
by: Naoto Nagata, et al.
Published: (2022-06-01)

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
by: Ho Soo Chun, et al.
Published: (2023-04-01)

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
by: Jihyun An, et al.
Published: (2023-02-01)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
by: Bing Yang, et al.
Published: (2023-09-01)